Editas Medicine Announces First Quarter 2024 Results and Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Editas Medicine (EDIT) PT Lowered to $15 at Citi
May 8, 2024 4:01 PM EDTCiti analyst Samantha Semenkow lowered the price target on Editas Medicine (NASDAQ: EDIT) to $15.00 (from $16.00) while maintaining a Buy rating.
The analyst comments "On the call this morning, CSO Linda Burkly outlined Editas in vivo pipeline strategy. Editas will focus efforts on functionally... More
